Targeted therapies in gynaecological cancers

Shanthini Mary Crusz(Barts Health NHS Trust), Rowan Miller(University College Hospital)

Histopathology

December 17, 2019

10.1111/his.14009

Cited by 36

Related Papers

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer

|Annals of Oncology|2020|478

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

|Nature Communications|2016|386

Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

|Annals of Oncology|2023|381

Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity

|Cancer Research|2013|367

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group

|Annals of Oncology|2024|343